ATOPIC DERMATITIS ADVISOR

Patient Preparatory Guidance for Topical JAK Inhibitors

DECEMBER 21, 2021

Matthew Zirwas, MD, provides guidance on speaking with patients with atopic dermatitis about treating their condition with topical JAK inhibitors. 

An Overview of Janus-kinase (JAK) inhibitors for Atopic Dermatitis

DECEMBER 1, 2021

Matthew Zirwas, MD, discusses the efficacy, benefits, and safety profile of topical and systemic JAK inhibitors for the treatment of atopic dermatitis. 

ATOPIC DERMATITIS IN THE NEWS

New Study Shows Black Americans Face Higher Out-of-Pocket Costs Related to Atopic Dermatitis
The National Eczema Association research team has published its third paper on the out-of-pocket (OOP) costs of atopic dermatitis (AD) in the United States – this time in the Archives of Dermatological Research. The first publication revealed how much money Americans with AD spend OOP to manage their condition. The second publication established a correlation between increased OOP costs and increased severity of AD.

Read More

 

Increased Risk of Fracture Found in Children With Atopic Dermatitis
New study findings published in Pediatric Allergy and Immunology suggest that the risk of bone fractures may be elevated in children with atopic dermatitis (AD). Fractures have been cited as risk factors for patients with inadequately controlled AD due to the impaired bone health, and studies of adults with AD have indicated that the increased risk for fracture in those with inadequately controlled disease is linked to the use of systemic corticosteroids and their consequent impact on bone mineral density.

Read More

 

Sleep Disturbances More Profound in Older Adults With Atopic Dermatitis
According to new research presented during a poster session at the Revolutionizing Atopic Dermatitis virtual symposium, patients ages 65 years and older with atopic dermatitis have similar disease severity when compared with younger adult patients, but they have more profound sleep disturbances.

Read More

 

The Human Skin Microbiome and its Changes in Atopic Dermatitis
In this article, an expert from the National Eczema Association explores how the microbiome is affected in atopic dermatitis and how manipulating the skin microbiome is being investigated as a new type of treatment approach.

Read More

 

Probiotic Supplementation for Prevention of Atopic Dermatitis in Infants and Children
Probiotic supplementation in childhood may be useful in avoiding atopic dermatitis (AD), but findings concerning this regimen’s effectiveness have been mixed. In this review, researchers examined the influence of probiotic supplementation on the risk of AD. Researchers found that probiotic supplementation during both the prenatal and the postnatal period reduced the incidence of AD in infants and children, which suggests that starting such treatment during gestation and continuing through the first 6 months of the infant’s life may be beneficial in preventing AD.

Read More

 

Atopic Dermatitis Severity, Age at Diagnosis May Increase Risk of Ophthalmic Diseases

This cross-sectional, questionnaire-based survey sought to examine the prevalence of ocular surface diseases (OSDs) in adults with AD and identify patient characteristics and risk factors. The nationwide study was conducted in Denmark and included adults with a diagnosis of atopic dermatitis registered in the National Patient Register. About 7,000 patients responded to the survey. Factors associated with lifetime occurrence of conjunctivitis included mild, moderate, and severe AD, asthma bronchiale and, childhood-onset of AD, and systemic AD treatment.

Read More

 

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis

Incyte has announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable.

Read More

 

Prenatal Exposure to Metals May Increase Risk of Atopic Dermatitis in Children

This study sought to assess the association between prenatal exposure to arsenic and other metals and the occurrence of atopic dermatitis in children at age 4 years. Here, the authors performed statistical analysis of data on 370 mother and child pairs from the Taiwan Maternal and Infant Cohort Study (TMICS). A total of 110 children (29.7%) had atopic dermatitis at age 4 years, and maternal estimated total inorganic arsenic exposure during pregnancy was associated with increased odds of atopic dermatitis among children at age 4 years.

Read More

 

Machine Learning–Based Deep Phenotyping of Atopic Dermatitis: Severity-Associated Factors in Adolescent and Adult Patients

In this study, the authors performed deep phenotyping and identification of severity-associated factors in adolescent and adult patients with atopic dermatitis. Patients were stratified by severity groups using the Eczema Area and Severity Index (EASI) and the associations of 130 factors with AD severity were analyzed using machine learning.

Read More

 

Nonpharmacological Approaches to Managing Atopic Dermatitis

Watch Lawrence Eichenfield, MD, Raj Chovatiya, MD, PhD, Leon Kircik, MD, Peter Lio, MD, and Elizabeth Swanson, MD discuss nonpharmacological strategies to treat atopic dermatitis and improve patient quality of life.

Read More